TY - JOUR
T1 - Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma
T2 - A Multicenter Retrospective Analysis
AU - Buettner, Stefan
AU - Braat, Arthur J A T
AU - Margonis, Georgios Antonios
AU - Brown, Daniel B
AU - Taylor, Kevin B
AU - Borgmann, Anthony J
AU - Kappadath, S Cheenu
AU - Mahvash, Armeen
AU - IJzermans, Jan N M
AU - Weiss, Matthew J
AU - Lamarca, Angela
AU - Bell, Jon K
AU - Valle, Juan W
AU - Hagendoorn, Jeroen
AU - Koerkamp, Bas Groot
AU - Sze, Daniel Y
AU - Lam, Marnix G E H
N1 - Funding Information:
A.J.A.T.B. receives speaker fees from Sirtex Medical (Sydney, Australia), BTG International (London, United Kingdom), and Terumo (Tokyo, Japan). S.C.K. is a paid consultant for BTG International, ABK Biomedical (Halifax, Nova Scotia, Canada), and Terumo and receives research support from BTG International and Sirtex Medical. A.L. receives financial support from Sirtex Medical and Delcath (Queensbury, New York). D.B.B. receives research support from BTG International and Sirtex. D.Y.S. is a paid consultant for AstraZeneca (Cambridge, United Kingdom), BlackSwan Vascular (Hayward, California), Boston Scientific (Marlborough, Massachusetts), Bristol Myers Squibb (New York, New York), BTG International, Eisai (Tokyo, Japan), EmbolX (Sunnyvale, California), W.L. Gore & Associates (Flagstaff, Arizona), Koli Medical (Palo Alto, California), RadiAction Medical (Tel Aviv, Israel), and Terumo and owns equity in Confluent Medical (Fremont, California) and Proteus Digital Health (Redwood City, California). M.G.E.H.L. is a paid consultant for BTG International and Terumo and receives research support from BTG International, Terumo, and Quirem (Deventer, The Netherlands).
Funding Information:
S.B. received financial support from the Micha?l?van Vloten Foundation. A.L. was partially funded by The Christie Charity. A.J.A.T.B. receives speaker fees from Sirtex Medical (Sydney, Australia), BTG International (London, United Kingdom), and Terumo (Tokyo, Japan). S.C.K. is a paid consultant for BTG International, ABK Biomedical (Halifax, Nova Scotia, Canada), and Terumo and receives research support from BTG International and Sirtex Medical. A.L. receives financial support from Sirtex Medical and Delcath (Queensbury, New York). D.B.B. receives research support from BTG International and Sirtex. D.Y.S. is a paid consultant for AstraZeneca (Cambridge, United Kingdom), BlackSwan Vascular (Hayward, California), Boston Scientific (Marlborough, Massachusetts), Bristol Myers Squibb (New York, New York), BTG International, Eisai (Tokyo, Japan), EmbolX (Sunnyvale, California), W.L. Gore & Associates (Flagstaff, Arizona), Koli Medical (Palo Alto, California), RadiAction Medical (Tel Aviv, Israel), and Terumo and owns equity in Confluent Medical (Fremont, California) and Proteus Digital Health (Redwood City, California). M.G.E.H.L. is a paid consultant for BTG International and Terumo and receives research support from BTG International, Terumo, and Quirem (Deventer, The Netherlands).
Funding Information:
S.B. received financial support from the Michaël–van Vloten Foundation. A.L. was partially funded by The Christie Charity .
Publisher Copyright:
© 2020 SIR
PY - 2020/7
Y1 - 2020/7
N2 - PURPOSE: To report outcomes of yttrium-90 (90Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC).MATERIALS AND METHODS: Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with χ2 tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method.RESULTS: Grade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval [CI], 21-37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after 90Y radioembolization (4%).CONCLUSIONS: This study provides observational data of treatment outcomes after 90Y radioembolization in patients with unresectable ICC.
AB - PURPOSE: To report outcomes of yttrium-90 (90Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma (ICC).MATERIALS AND METHODS: Retrospective review was performed of 115 patients at 6 tertiary care centers; 92 were treated with resin microspheres (80%), 22 were treated with glass microspheres (19%), and 1 was treated with both. Postintervention outcomes were compared between groups with χ2 tests. Survival after diagnosis and after treatment was assessed by Kaplan-Meier method.RESULTS: Grade 3 laboratory toxicity was observed in 4 patients (4%); no difference in toxicity profile between resin and glass microspheres was observed (P = .350). Clinical toxicity per Society of Interventional Radiology criteria was noted in 29 patients (25%). Partial response per Response Evaluation Criteria In Solid Tumors 1.1 was noted in 25% of patients who underwent embolization with glass microspheres and 3% of patients who were treated with resin microspheres (P = .008). Median overall survival (OS) from first diagnosis was 29 months (95% confidence interval [CI], 21-37 mo) for all patients, and 1-, 3-, and 5-year OS rates were 85%, 31%, and 8%, respectively. Median OS after treatment was 11 months (95% CI, 8-13 mo), and 1- and 3-year OS rates were 44% and 4%, respectively. These estimates were not significantly different between resin and glass microspheres (P = .730 and P = .475, respectively). Five patients were able to undergo curative-intent resection after 90Y radioembolization (4%).CONCLUSIONS: This study provides observational data of treatment outcomes after 90Y radioembolization in patients with unresectable ICC.
UR - https://www.scopus.com/pages/publications/85085290260
U2 - 10.1016/j.jvir.2020.02.008
DO - 10.1016/j.jvir.2020.02.008
M3 - Article
C2 - 32473757
SN - 1051-0443
VL - 31
SP - 1035-1043.e2
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
IS - 7
ER -